Emsita-M 50/500 Tablet 15s

Uses of Emsita-M 50/500 Tablet 15s

Metformin and Sitagliptin is oral antidiabetic agent, prescribed for type 2 diabetes. It helps control blood sugar levels.

Side Effects of Emsita-M 50/500 Tablet 15s

Headache, diarrhoea, upper respiratory tract infection, nasopharyngitis. Angioedema, exfoliative dermatitis, hypoglycaemia. Potentially Fatal: Anaphylaxis and/or severe dermatologic reactions such as Stevens-Johnson syndrome.

Drug Interactions

Concurrent use may increase serum levels of digoxin. Increased risk of hypoglycaemia when used with sulphonylureas.

Contraindications

Type 1 diabetes. Diabetic ketoacidosis.

Mechanism of Action

Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV), resulting in prolonged active incretin levels. Incretin hormones increases insulin synthesis and release from pancreatic β-cells and reduces glucagon secretion from pancreatic α-cells. Reduced glucagon secretion leads to decreased hepatic glucose production. Absorption: Rapid absorption. Bioavailability: About 87%. Distribution: Protein binding: 38%. Metabolism: Not extensively metabolised. Excretion: Elimination half-life: 12 hr. 87% excreted in urine (mainly as unchanged drug) and 13% excreted in faeces.

Special Precautions

Discontinue treatment if there are signs of hypersensitivity. Caution when used with sulphonylureas and/or other antidiabetic medications; monitor blood glucose regularly. Renal impairment; dose adjustment may be needed. Children <18 yr. Pregnancy, lactation.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.